ReviewJournal of ovarian research2025
The implications of LncRNAs and premature ovarian insufficiency.
Review in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Review
- From Genes to Lives: Integrating the Complexities of Primary Ovarian Insufficiency.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Premature ovarian insufficiency (POI) is a complex disorder characterized by hypoestrogenism, elevated gonadotropins, and menstrual irregularity or amenorrhea. Effective treatments remain limited, but advances in reproductive biology have highlighted long noncoding RNAs (lncRNAs) as pivotal regulators of granulosa cell function and follicular development. Growing evidence shows that lncRNAs contribute to POI pathogenesis and hold promise as diagnostic biomarkers and therapeutic targets. This review summarizes recent findings on the lncRNA-mediated regulation of granulosa cell proliferation, autophagy, apoptosis, hormone signalling, mitochondrial stress, glycolysis, and DNA damage and discusses current limitations—including small sample sizes, limited in vivo validation, and translational challenges—that hinder clinical application. Although lncRNAs represent an emerging frontier in POI research, their diagnostic and therapeutic value requires further validation before clinical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.